Scholarlink

Background <p>Oral squamous cell carcinoma (OSCC) exhibits poor prognosis due to aggression, metastasis, and chemoresistance. Protein Arginine Methyltransferase 1 (PRMT1) and Signal Transducer and Activator of Transcription 3 (STAT3) are implicated in oncogenesis, but their interplay and downstream effects, particularly concerning ferroptosis and immune evasion in OSCC remain unclear.</p> Results <p>PRMT1 was significantly upregulated in OSCC tissues and cell lines, correlating with advanced grade, metastasis, and poor patient survival. PRMT1 knockdown inhibited OSCC proliferation, invasion, metastasis, and chemoresistance in vitro and in vivo. Mechanistically, PRMT1 directly interacted with, methylated, and activated STAT3 (increased p-STAT3 and target genes VEGFA, IL-6, c-myc). The PRMT1/STAT3 axis suppressed ferroptosis; PRMT1 knockdown decreased GPX4 expression, increased Fe2 + , ROS, and MDA, and decreased GSH, effects rescued by STAT3 overexpression. STAT3 directly bound and activated the GPX4 promoter. Crucially, inhibiting ferroptosis with liproxstatin-1 reversed the anti-tumor effects (chemosensitization, reduced proliferation/invasion) of PRMT1 knockdown. PRMT1 KO also enhanced anti-PD-1 therapy efficacy in vivo.</p> Conclusion <p>PRMT1 drives OSCC aggressiveness by methylating and activating STAT3. This axis promotes chemoresistance and oncogenic phenotypes primarily by suppressing ferroptosis through STAT3-mediated transcriptional upregulation of GPX4. Targeting PRMT1 represents a promising strategy to overcome chemoresistance and inhibit progression in OSCC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

PRMT1 drives oral squamous cell carcinoma progression by activating STAT3 and suppressing ferroptosis via GPX4

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月24日

查看全文
  • Huawei Liu,
  • Chuyan Shi,
  • Bing Liu,
  • Bo Wei,
  • Yingying Wu,
  • Peng Chen

摘要

Background

Oral squamous cell carcinoma (OSCC) exhibits poor prognosis due to aggression, metastasis, and chemoresistance. Protein Arginine Methyltransferase 1 (PRMT1) and Signal Transducer and Activator of Transcription 3 (STAT3) are implicated in oncogenesis, but their interplay and downstream effects, particularly concerning ferroptosis and immune evasion in OSCC remain unclear.

Results

PRMT1 was significantly upregulated in OSCC tissues and cell lines, correlating with advanced grade, metastasis, and poor patient survival. PRMT1 knockdown inhibited OSCC proliferation, invasion, metastasis, and chemoresistance in vitro and in vivo. Mechanistically, PRMT1 directly interacted with, methylated, and activated STAT3 (increased p-STAT3 and target genes VEGFA, IL-6, c-myc). The PRMT1/STAT3 axis suppressed ferroptosis; PRMT1 knockdown decreased GPX4 expression, increased Fe2 + , ROS, and MDA, and decreased GSH, effects rescued by STAT3 overexpression. STAT3 directly bound and activated the GPX4 promoter. Crucially, inhibiting ferroptosis with liproxstatin-1 reversed the anti-tumor effects (chemosensitization, reduced proliferation/invasion) of PRMT1 knockdown. PRMT1 KO also enhanced anti-PD-1 therapy efficacy in vivo.

Conclusion

PRMT1 drives OSCC aggressiveness by methylating and activating STAT3. This axis promotes chemoresistance and oncogenic phenotypes primarily by suppressing ferroptosis through STAT3-mediated transcriptional upregulation of GPX4. Targeting PRMT1 represents a promising strategy to overcome chemoresistance and inhibit progression in OSCC.